Literature DB >> 27087380

[Chinese expert consensus on diagnosis and treatment of soft tissue sarcomas (Version 2015)].

.   

Abstract

Soft tissue sarcoma is a group of malignancies of mesenchymal origin. It arises from almost every part of human body in all decades. Appropriate dagnosis and treatment of soft tissue sarcoma are always challenging to physicians and pathologists because of its extremely low incidence and variable biological behaviors among subtypes. Surgical resection remains the most important and only method to cure soft tissue sarcomas, while chemoradiation and target therapy are incorporated into multidisciplinary treatment model, but there is no generally accepted consensus on how to do multidisciplinary treatment properly and maximize the therapeutic effects. The aim of this article is to improve the understanding of multidisciplinary treatment of soft tissue sarcomas and to provide a guidance nationwide based on evidence-based medicine and expert's experience on related topics.

Entities:  

Mesh:

Year:  2016        PMID: 27087380     DOI: 10.3760/cma.j.issn.0253-3766.2016.04.013

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  5 in total

1.  Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study.

Authors:  Akira Kawai; Hiroyuki Narahara; Shunji Takahashi; Tomoki Nakamura; Hiroshi Kobayashi; Yasunori Megumi; Toshiyuki Matsuoka; Eisuke Kobayashi
Journal:  BMC Cancer       Date:  2022-05-11       Impact factor: 4.638

2.  Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.

Authors:  Xia Yang; Wen-Ting Huang; Rong-Quan He; Jie Ma; Peng Lin; Zu-Cheng Xie; Fu-Chao Ma; Gang Chen
Journal:  J Transl Med       Date:  2019-08-23       Impact factor: 5.531

3.  DNA methylation patterns-based subtype distinction and identification of soft tissue sarcoma prognosis.

Authors:  Kai Li; Zhengyuan Wu; Jun Yao; Jingyuan Fan; Qingjun Wei
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

Review 4.  Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas.

Authors:  Zhichao Tian; Weitao Yao
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

5.  Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study.

Authors:  Zhichao Tian; Yonghao Yang; Jinpo Yang; Peng Zhang; Fan Zhang; Xinhui Du; Chao Li; Jiaqiang Wang
Journal:  Cancer Manag Res       Date:  2020-02-24       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.